Artificial Intelligence Regulation Article Pack

Every drug sponsor wants to make the best use of artificial intelligence, but doing so requires understanding where health authorities are drawing the lines. That’s always something of a moving target, especially in a field as new as AI. The Pink Sheet’s globe-spanning coverage has produced one rule of thumb, however: The closer AI is to patient care, the more scrutiny it will get. Regulators seem content to allow firms to make product development decisions based on AI without significant oversight.

Download a sample of our coverage from Asia, Europe, and the United States of the emerging framework for artificial intelligence regulation.

''
Citeline may contact you about relevant products, services and content. To opt-out of these communications or to manage what you receive, please visit our Preference Center.

Your information will be used in accordance with our Privacy notice.

Thank you.




Your download should open in a new window. You can also manually download by clicking the button below.



Related resources

OCT 30, 2024
Article
薬事規制関連支援サービス

EU’s Pharma Legislative Reform

Every drug sponsor wants to make the best use of Artificial Intelligence, but doing so requires understanding where health authorities are drawing the lines. Download a sample of our coverage from Asia, Europe and the United States of the emerging framework for AI regulation.

AI
OCT 11, 2024
Whitepaper
Clinical

【日本語版】製薬業界におけるAI:リスク、リターン、そして今後の展望

AIは、研究から承認、マーケティングに至るまで、医薬品開発プロセスのあらゆるステップを効率化・加速するために活用されています。

a person's hand holding a device with an AI interface
JUN 07, 2023
Article
商業化支援サービス

EU AI Act Legal Deep-Dive Part 1: What Can Medtech Expect, and When?

Members of the European Parliament voted in favor of substantial changes to the draft AI Act, which has since been passed into law.